Roy S. Herbst is affiliated with the Yale Cancer Center.[1]He specializes in oncology and medicine.[23]
Herbst is the ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at the Yale Cancer Center and Yale School of Medicine.[4]He is best known for his work in the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.[5]His research has explored predictive biomarkers for the use of immunotherapy agents and is he serves as one of the principal investigators of the NCI lung cancer master protocol.[6]Although activating the immune system has shown to be a successful goal for cancer treatment, he did note that it can result in immune-related adverse effects in various body systems:[7]Dr. Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstractsand book chapters.[8]He is also a member of the Oncology Report editorial board.[9]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Yale Cancer Center
7
1070
326
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community. “The work of Dr. Herbst and his team has importantly led to the approval of several treatments that have revolutionized lung cancer care, improved patient survival, and changed patient expectations."[15]
12/17/2020
More than 200,000 people a year in the United States are diagnosed with non-small cell lung cancers, which make up about 80% of all lung cancers. Now, the results of a phase-three clinical trial show the immunotherapy drug atezolizumab, also known as Tecentriq, improves survival. "There was 40-plus percent improvement in survival in those patients who got the immunotherapy, the atezolizumab, versus the chemotherapy," said Dr. Roy Herbst, the chief of medical oncology at Yale Cancer Center.[16]
11/30/2020
Please provide your email address to receive an email when new articles are posted on. We were unable to process your request. Please try again later. Roy S. Herbst, MD, PhD, Yale Cancer Center and Smilow Cancer Hospital, discusse lectures given by both the current president of the International Association for the Study of Lung Cancer, Tetsuya Mitsudomi, MD, and past president, Giorgio Scagliotti, MD, PhD.[18]
08/11/2020